Long-term remission & control of CVD risk factors can reduce the risk of atherosclerosis in lupus; triple APL positivity raises the risk of CVD, study finds.
Search results for: cardiovascular risk
Cardiovascular Risks Similar for JAK Inhibitors & bDMARDs
Using data from registries across Europe and Canada, Aymon et al. compared the incidence of major adverse cardiac events (MACE) in patients with RA treated with JAK inhibitors, TNF inhibitors or biologic DMARDs with other modes of action over two years. The researchers did not find an increased risk of MACE with JAK inhibitors over that time frame.
Study Finds Potential Biomarkers for Cardiovascular Risk in Women with Lupus
When it comes to systemic lupus erythematosus (SLE) and cardiovascular events (CVEs), the rheumatology community is woefully lacking in information, say researchers from the University of California, Los Angeles (UCLA) David Geffen School of Medicine and Cedars-Sinai Medical Center. Their recent work on biomarkers associated with an increased risk for cardiovascular events in women with…
Cardiovascular Risks & Insights from ACR Convergence 2021
Experts share insights into how LDL & HDL levels are affected by inflammation & the treatment of rheumatic disease, addressing how targeting these levels may improve cardiovascular outcomes for patients.
Practical Ways to Manage Cardiovascular Risk in Patients with Psoriatic Arthritis
Increased cardiovascular (CV) risk in patients with rheumatic disease is old news. Over the past decade, a multitude of studies have demonstrated elevated CV risk in a variety of conditions: systemic lupus erythematosus, rheumatoid arthritis and psoriatic arthritis (PsA), to name a few. The risk in patients with rheumatic disease seems to be linked to…
Study Examines Tofacitinib’s Long-Term Cardiovascular Risk & More
In a post-marketing safety study, tofacitinib did not prove non-inferior to tumor necrosis factor inhibitors when evaluated for its long-term effects on heart disease, malignancies and serious infections in RA patients.
Cardiovascular Risk in Rheumatoid Arthritis: Pathogenesis, Screening & Prevention
SNOWMASS VILLAGE, COLO.—Even in the era of treat to target, cardiovascular disease risk remains elevated and is a major source of mortality and morbidity in patients with rheumatoid arthritis (RA). Screening and management of cardiovascular risk in these patients is critical to ensure these patients are identified and treated. At the 2019 ACR Winter Rheumatology…
Walking Ability of OA Patients Linked to Cardiovascular Risk
New research explores the association of the ability to walk and the risk of cardiovascular disease in OA patients compared with the general population. During the study, researchers recorded a six-minute walking distance and measured arterial stiffness of participants. The results: Even among younger people, OA patients could not walk as far as those in the general population. Also, arterial stiffness was inversely associated with walking distance, suggesting walking is important to the cardiovascular risk profile of OA patients…
Identifying Cardiovascular Risk Factors in Psoriatic Arthritis
Psoriatic arthritis (PsA), like other inflammatory diseases, has been associated with increased incidence for and mortality from cardiovascular disease (CVD), the most common comorbidity leading to death in many conditions treated by rheumatologists. But beyond recognizing the burden of increased inflammation, the mechanisms behind this association are not well understood, says M. Elaine Husni, MD,…
Video Education: Patient Outreach Effort Offers Education about Cardiovascular Risks
Experts in rheumatoid arthritis, cardiovascular health and education have joined forces to create a video intervention designed to help patients understand their risks for heart attack and stroke, as well as how to reduce these risks. Early research into this educational intervention shows the video is effective…
- 1
- 2
- 3
- …
- 60
- Next Page »